王座失落之后,默沙东6000人大裁员

经济观察报
Aug 07

过去十年,凭借“药王”Keytruda(K药,帕博利珠单抗)和HPV疫苗这两大明星单品,默沙东制药业务收入在一众跨国药企(MNC)中长期排在前列。现在,随着K药增速明显放缓,以及HPV疫苗从一针难求到卖不动的反转,默沙东按下了减速键。7月29日,世界制药巨头默沙东披露了上半年惨淡的业绩:总营收313亿美元,同比下降2%;制药业务收入277亿美元,同比下滑3%;中国区收入约11亿美元,同比暴跌70%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10